链激酶和茴香酰化纤溶酶原链激酶激活剂复合物在急性心肌梗死中的药代动力学特性比较。
A comparison of the pharmacokinetic properties of streptokinase and anistreplase in acute myocardial infarction.
作者信息
Gemmill J D, Hogg K J, Burns J M, Rae A P, Dunn F G, Fears R, Ferres H, Standring R, Greenwood H, Pierce D
机构信息
Department of Medicine, University of Glasgow, Stobhill General Hospital.
出版信息
Br J Clin Pharmacol. 1991 Feb;31(2):143-7. doi: 10.1111/j.1365-2125.1991.tb05502.x.
Abstract
- The pharmacokinetics of streptokinase (SK) and anistreplase in conventional dosage regimens of 1.5 x 10(6) i.u. of SK infused over 60 min and 30 units of anistreplase over 5 min were studied in 24 consecutive patients presenting with acute myocardial infarction, using a functional bioassay to assess concentrations. 2. The two agents were found to have similar volumes of distribution (5.68 and 5.90 l), but SK was cleared significantly more rapidly than anistreplase, resulting in a shorter terminal phase half-life (0.61 vs 1.16 h) and a shorter mean residence time (0.76 vs 1.55 h).
摘要
- 在24例连续的急性心肌梗死患者中，研究了链激酶（SK）和茴香酰化纤溶酶原链激酶激活剂复合物（APSAC）在常规剂量方案下的药代动力学，其中SK剂量为1.5×10⁶国际单位，在60分钟内输注完毕，APSAC剂量为30单位，在5分钟内输注完毕，采用功能性生物测定法评估浓度。2. 发现这两种药物的分布容积相似（分别为5.68升和5.90升），但SK的清除速度明显快于APSAC，导致终末相半衰期较短（分别为0.61小时和1.16小时），平均驻留时间也较短（分别为0.76小时和1.55小时）。
相似文献
1
A comparison of the pharmacokinetic properties of streptokinase and anistreplase in acute myocardial infarction.
Br J Clin Pharmacol. 1991 Feb;31(2):143-7. doi: 10.1111/j.1365-2125.1991.tb05502.x.
2
Invasive reperfusion study. II. Multicentre European randomized trial of anistreplase vs streptokinase in acute myocardial infarction.
Eur Heart J. 1991 Feb;12(2):179-85. doi: 10.1093/oxfordjournals.eurheartj.a059866.
3
Comparison of results of intravenous infusion of anistreplase versus streptokinase in acute myocardial infarction.
Am J Cardiol. 1993 Feb 1;71(4):274-80. doi: 10.1016/0002-9149(93)90790-j.
4
Effects of early thrombolytic therapy (anistreplase versus streptokinase) on enzymatic and electrocardiographic infarct size in acute myocardial infarction. TEAM-2 Investigators.
Am J Cardiol. 1991 Oct 1;68(9):848-56. doi: 10.1016/0002-9149(91)90398-5.
5
Acylated plasminogen-streptokinase activator complex: a new approach to thrombolytic therapy.
Pharmacotherapy. 1990;10(2):115-26.
6
High-dose systemic streptokinase and acylated streptokinase-plasminogen complex (BRL 26921) in acute myocardial infarction: alterations of the fibrinolytic system and clearance of fibrinolytic activity.
Haemostasis. 1987;17(1-2):32-9. doi: 10.1159/000215556.
7
Summary of U.S. clinical trials program for evaluation of anistreplase.
Clin Cardiol. 1990 Mar;Suppl 5:V33-8; discussion V67-72. doi: 10.1002/clc.4960131309.
8
Pharmacokinetic properties of anisoylated plasminogen streptokinase activator complex and other thrombolytic agents in animals and in humans.
Drugs. 1987;33 Suppl 3:88-92. doi: 10.2165/00003495-198700333-00013.
9
[Effects of anistreplase on coronary patency in acute myocardial infarction].
Arch Mal Coeur Vaiss. 1990 Feb;83 Spec No 1:25-9.
10
Plasminogen activators: a comparison.
Vascul Pharmacol. 2006 Jan;44(1):1-9. doi: 10.1016/j.vph.2005.09.003. Epub 2005 Nov 7.
引用本文的文献
1
Co-ordinated spatial propagation of blood plasma clotting and fibrinolytic fronts.
PLoS One. 2017 Jul 7;12(7):e0180668. doi: 10.1371/journal.pone.0180668. eCollection 2017.
2
Effect of streptokinase on reperfusion after acute myocardial infarction and its complications: an ex-post facto study.
Glob J Health Sci. 2015 Jan 1;7(4):184-9. doi: 10.5539/gjhs.v7n4p184.
3
A rapid agglutination assay to detect anti-streptokinase antibodies.
Ir J Med Sci. 2004 Oct-Dec;173(4):204-10. doi: 10.1007/BF02914552.
4
Circulatory concentrations of fibrinolytic species during thrombolytic therapy estimated by stirred-tank reactor analysis.
Pharm Res. 1997 Aug;14(8):1051-7. doi: 10.1023/a:1012157429573.
5
Streptokinase. A review of its pharmacology and therapeutic efficacy in acute myocardial infarction in older patients.
Drugs Aging. 1994 Jan;4(1):63-86. doi: 10.2165/00002512-199404010-00007.
6
Drug interactions with thrombolytic agents. Current perspectives.
Clin Pharmacokinet. 1995 Apr;28(4):315-26. doi: 10.2165/00003088-199528040-00004.
本文引用的文献
1
The clearance of heterologous protein from the circulation of normal and immunized man.
J Clin Invest. 1958 Sep;37(9):1306-15. doi: 10.1172/JCI103719.
2
The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time.
J Pharmacokinet Biopharm. 1980 Oct;8(5):509-34. doi: 10.1007/BF01059549.
3
Treatment of myocardial infarction with intracoronary streptokinase: efficacy and safety data from 209 United States cases in the Hoechst-Roussel registry.
Am Heart J. 1982 Oct;104(4 Pt 2):894-8. doi: 10.1016/0002-8703(82)90262-9.
4
A randomized trial of IV streptokinase in evolving acute myocardial infarction: an assessment by selective coronary angiography.
Indian Heart J. 1984 Nov-Dec;36(6):339-46.
5
A randomized trial of intravenous and intracoronary streptokinase in patients with acute myocardial infarction.
Circulation. 1984 Oct;70(4):606-18. doi: 10.1161/01.cir.70.4.606.
6
The effects of the rate of intravenous infusion of streptokinase and the duration of symptoms on the time interval to reperfusion in patients with acute myocardial infarction.
Circulation. 1985 Nov;72(5):1053-8. doi: 10.1161/01.cir.72.5.1053.
7
Acute myocardial infarction treated with intracoronary streptokinase: a report of the Society for Cardiac Angiography.
Am J Cardiol. 1985 Apr 1;55(8):871-7. doi: 10.1016/0002-9149(85)90709-x.
8
Coronary thrombolysis with intravenous anisoylated plasminogen-streptokinase complex BRL 26921.
Br Heart J. 1985 Mar;53(3):253-9. doi: 10.1136/hrt.53.3.253.
9
Pharmacokinetics of streptokinase in patients based on amidolytic activator complex activity.
Clin Pharmacol Ther. 1987 Mar;41(3):304-13. doi: 10.1038/clpt.1987.32.
10
High-dose, brief-duration intravenous infusion of streptokinase in acute myocardial infarction: description of effects in the circulation.
Am J Cardiol. 1986 Jun 1;57(15):1220-6. doi: 10.1016/0002-9149(86)90192-x.
Zotero 插件